Direct Visualization of Optical Activity in Chiral Substances Using a Helical Nanofilament (B4) Liquid Crystal Phase
Source abstract
Abstract
Abstract Detecting the chirality of material is very important in material science, chemistry, pharmacology, and biomaterial science because it is useful for identifying and discarding unintended side effects. Here, directly visualized is the optical activity of chiral samples using an orientation‐controlled helical nanofilament (HNF, B4) liquid crystal (LC) phase made of achiral bent‐shaped molecules. The vertical orientation of the HNFs is induced by shining unpolarized UV light. Right‐ or left‐handed domains of the HNFs are formed because of the lack of molecular chirality, each single‐handed domain is large enough to be seen with the naked eye, up to ≈several mm2. The periodic arrays of aligned HNFs reflect a specific color, here green, due to the Bragg reflection. Such a reflector enables an easy detection of optical activity of a sample placed on it. The device is tested with naturally chiral substances, like fructose and glucose, which exhibit opposite sense of optical activity, as well as with structurally chiral nematic LC phase and reveals high sensitivity of a detection.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Liquid Crystal Research Advancements · Molecular spectroscopy and chirality · Metamaterials and Metasurfaces Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Graduate School of Nanoscience and Technology Korea Advanced Institute of Science and Technology Daejeon 34141 Republic of Korea
Faculty of Chemistry University of Warsaw Warsaw 02‐089 Poland
Department of Chemistry and KINC Korea Advanced Institute of Science and Technology Daejeon 34141 Republic of Korea
Funding
National Research Foundation · Ministry of Education · Narodowe Centrum Nauki
References (29)
Show source-provided references
1. 10.1021/cr400568b10.1021/cr400568b ↗
2. Mohan S. J. · Int. J. Pharm. Sci. Nanotechol. · 2009 · 1 · 309
3. 10.1021/nl304638a10.1021/nl304638a ↗
4. Berova N. · 2000
5. 10.1002/978111812039210.1002/9781118120392 ↗
6. 10.1038/ncomms318810.1038/ncomms3188 ↗
7. 10.1002/chir.2047310.1002/chir.20473 ↗
8. 10.1039/C7AN01855J10.1039/C7AN01855J ↗
9. 10.1039/C4RA10416A10.1039/C4RA10416A ↗
10. 10.1103/PhysRevLett.102.11390210.1103/PhysRevLett.102.113902 ↗
11. 10.1016/j.jpba.2006.06.01510.1016/j.jpba.2006.06.015 ↗
12. 10.1038/ncomms170910.1038/ncomms1709 ↗
13. 10.1038/ncomms473510.1038/ncomms4735 ↗
14. 10.1038/382522a010.1038/382522a0 ↗
15. 10.1039/c1cc10400d10.1039/c1cc10400d ↗
16. 10.1039/C5SM03100A10.1039/C5SM03100A ↗
17. 10.1126/science.117002710.1126/science.1170027 ↗
18. 10.1002/smll.20160088210.1002/smll.201600882 ↗
19. 10.1038/ncomms430210.1038/ncomms4302 ↗
20. 10.1021/acs.nanolett.5b0076010.1021/acs.nanolett.5b00760 ↗
21. 10.1002/adma.20160273710.1002/adma.201602737 ↗
22. 10.1002/adma.20170316510.1002/adma.201703165 ↗
23. 10.1038/nature1714110.1038/nature17141 ↗
24. 10.1002/adma.20180133510.1002/adma.201801335 ↗
25. 10.1039/C3TC32325K10.1039/C3TC32325K ↗
26. 10.1038/nature1934410.1038/nature19344 ↗
27. 10.1039/C7SM00115K10.1039/C7SM00115K ↗
28. 10.1038/s41427-019-0146-610.1038/s41427-019-0146-6 ↗
29. 10.1119/1.234062910.1119/1.2340629 ↗